An innovative minimally invasive, active medical device platform for remote neurological monitoring of brain cancer patients to aid treatment/care

创新的微创主动医疗设备平台，用于对脑癌患者进行远程神经学监测，以帮助治疗/护理

• 批准号: 10099579
• 金额: $ 44.14万
• 依托单位: OPTO BIOSYSTEMS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10099579
• 关键词: innovative; minimally; invasive; active; medical

Opto is a UK-based medical device SME with a core project team of Dr Ben Woodington (CEO), Dr Elise Jenkins (Project Lead/CTO) and Jose Lepe (Product Lead).Electrical monitoring devices are crucial for managing neurological diseases such as brain cancer, epilepsy, and Parkinson's disease. These conditions affect around 105K people annually in the UK alone. Unfortunately, current technologies have made little headway with remote treatment, as they are invasive, uncomfortable and require hospital monitoring, which limits their use to short periods and restricts at-home use. This is problematic for two reasons. First, managing these diseases costs the NHS over £2B per year, and patients lose around £3B in productivity due to ongoing assessments. Secondly, infrequent, inconsistent 'snapshot' assessments of neurological health do not provide the full benefits of the technology, which could help guide treatment, inform disease progression and provide advance warning to patients.People who do not live near major hospitals with advanced facilities (~20 % of UK residents) and lower-income groups who lack the means to travel for treatment regularly are disproportionately affected by this.Opto has developed a minimally invasive, active medical technology platform that enables remote neurological monitoring of brain cancer patients to aid disease treatment and management. This innovation will improve the quality of life of patients suffering from neurological diseases, starting with brain cancer.

Opto 是一家总部位于英国的医疗设备中小企业，核心项目团队由 Ben Woodington 博士（首席执行官）、Elise Jenkins 博士（项目负责人/首席技术官）和 Jose Lepe（产品负责人）组成。电子监测设备对于治疗脑癌、癫痫和帕金森病等神经系统疾病至关重要。仅在英国，这些病症每年就会影响约 10.5 万人。不幸的是，当前的技术在远程治疗方面进展甚微，因为它们是侵入性的、不舒服的并且需要医院监测，这限制了它们的短期使用并限制了家庭使用。由于两个原因，这是有问题的。首先，NHS 每年因管理这些疾病而花费超过 20 亿英镑，而患者因持续评估而损失了约 30 亿英镑的生产力。其次，对神经系统健康状况的不频繁、不一致的“快照”评估并不能提供该技术的全部好处，而该技术可以帮助指导治疗、告知疾病进展并向患者提供提前警告。居住在设施先进的大医院附近的人（约占英国居民的 20%）和缺乏定期前往治疗手段的低收入群体受到的影响尤为严重。Opto 开发了一种微创、 主动医疗技术平台能够对脑癌患者进行远程神经学监测，以帮助疾病治疗和管理。这项创新将改善神经系统疾病患者的生活质量，首先是脑癌。